Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTC PINK OTC PINK Primary 
Siemens Healthineers Core Businesses Offset Currency, Tariff Challenges
Revenue grew on a comparable basis as results in its imaging and precision therapy business units offset currency and tariff headwinds.
Siemens Healthineers beats Q1 profit estimates on strong imaging unit margins
Siemens Healthineers reported first-quarter operating profit above market expectations on Thursday, as strong margin performance in its core imaging and cancer-care units helped cushion a slump in its diagnostics business and adverse currency exchange rates.
Siemens Healthineers: Potentially Much Stronger Than Siemens In 2026E
Siemens Healthineers (SEMHF) is undervalued, offering strong safety and upside, and remains a top 'BUY' pick for 2026. Key risks center on muted China growth, but ex-China performance is robust, with Imaging and Varian segments driving future gains. I maintain my share price target, with fair value estimates, implying 15%+ annualized upside even with conservative assumptions.
Siemens Healthineers AG (SMMNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Siemens Healthineers AG (SMMNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Siemens Healthineers AG (SMMNY) Analyst/Investor Day Transcript
Siemens Healthineers AG (OTCPK:SMMNY) Analyst/Investor Day November 17, 2025 8:00 AM EST Company Participants Bernhard Montag - President, CEO & Chairman of Management Board Jochen Schmitz - CFO & Member of Management Board Andre Hartung - Head of Diagnostic Imaging Marc Koebernick - Head of Investor Relations Arthur Kaindl - Head of Varian Carsten Bertram - Head of Advanced Therapies Dorin Comaniciu Conference Call Participants Veronika Dubajova - Citigroup Inc., Research Division David Adlington - JPMorgan Chase & Co, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Graham Doyle - UBS Investment Bank, Research Division Hugo Solvet - BNP Paribas, Research Division Julien Ouaddour - BofA Securities, Research Division Julien Dormois - Jefferies LLC, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Oliver Reinberg - Kepler Cheuvreux, Research Division Andrew Hemming Presentation Operator Great. So when we set off the plan this day, by the way, thanks to Jefferies for giving us kind of a bit of a room within their huge conference.
Siemens Healthineers: Healthcare Remains Attractive After 2025
Siemens Healthineers remains a Buy, offering 15% annualized upside. Strong 2025 results, margin expansion, and resilient growth in Imaging and Varian segments support the investment case, despite China and tariff headwinds. Risks include ongoing diagnostics transformation, Chinese market uncertainty, and tariff impacts, but these are factored into current valuation and outlook.
Siemens Healthineers AG (SMMNY) Q4 2025 Press Conference Call Transcript
Siemens Healthineers AG (OTCPK:SMMNY) Q4 2025 Press Conference Call November 5, 2025 4:00 AM EST Company Participants Matthias Kraemer Bernhard Montag - President, CEO & Chairman of Management Board Jochen Schmitz - CFO & Member of Management Board Presentation Matthias Kraemer Good morning, ladies and gentlemen. Welcome to our annual press conference for fiscal 2025.
Siemens Healthineers AG (SMMNY) Q4 2025 Earnings Call Transcript
Siemens Healthineers AG (OTCPK:SMMNY) Q4 2025 Earnings Call November 5, 2025 2:00 AM EST Company Participants Marc Koebernick - Head of Investor Relations Bernhard Montag - President, CEO & Chairman of Management Board Jochen Schmitz - CFO & Member of Management Board Conference Call Participants Veronika Dubajova - Citigroup Inc., Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division David Adlington - JPMorgan Chase & Co, Research Division Julien Ouaddour - BofA Securities, Research Division Oliver Reinberg - Kepler Cheuvreux, Research Division Falko Friedrichs - Deutsche Bank AG, Research Division Julien Dormois - Jefferies LLC, Research Division Hugo Solvet - BNP Paribas, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Samuel England - Joh. Berenberg, Gossler & Co. KG, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers' Conference Call.
Siemens Healthineers Reports Fall in Profits, Citing Tariffs
Higher comparable revenue stemming from the transformation program of its diagnostics business was offset by a hit from U.S. tariffs.
Siemens Healthineers slightly misses sales expectations in fourth quarter
Siemens Healthineers on Wednesday reported fourth-quarter revenue slightly below analysts' consensus as higher U.S. import tariffs weigh.
Siemens AG Considers Spin-Off Of Siemens Healthineers Stake
Deal OverviewOn October 2, 2025, reports surfaced that Siemens AG (US OTC: SIEGY ADR, $142.89; Market Capitalization: $228.6 billion) is actively evaluating a potential spin-off of a substantial portion of its majority stake in Siemens Healthineers (US OTC: SMMNY ADR, $27.31; Market Capitalization: $61.6 billion), its publicly listed medical technology subsidiary.
Siemens Healthineers AG - Special Call
Siemens Healthineers AG - Special Call Company Participants Presentation Unknown Executive Welcome to our pre-close catch-up for Q4 fiscal year 2025, which was recorded on September 25, 2025. In this podcast, we sum up and repeat relevant topics, which were communicated in public as potentially relevant for the upcoming quarter.
